journal article·2022-02-02

Macrophage-Mimic Hollow Mesoporous Fe-Based Nanocatalysts for Self-Amplified Chemodynamic Therapy and Metastasis Inhibition via Tumor Microenvironment Remodeling

Wenbao Zuo, Weibin Chen, Jinxue Liu, Shuying Huang, Luping Chen, Qingna Liu, Nian Liu, Quanyi Jin, Yang Li, Peiyuan Wang, Xuan Zhu

Publisher page

Abstract

Fe-based nanomaterials with Fenton reaction activity are promising for tumor-specific chemodynamic therapy (CDT). However, most of the nanomaterials suffer from low catalytic efficiency due to its insufficient active site exposure and the relatively high tumor intracellular pH, which greatly impede its clinical application. Herein, macrophage membrane-camouflaged carbonic anhydrase IX inhibitor (CAI)-loaded hollow mesoporous ferric oxide (HMFe) nanocatalysts are designed to remodel the tumor microenvironment with decreased intracellular pH for self-amplified CDT. The HMFe not only serves as a Fenton agent with high active-atom exposure to enhance CDT but also provides hollow cavity for CAI loading. Meanwhile, the macrophage membrane-camouflaging endows the nanocatalysts with immune evading capability and improves tumoritropic accumulation by recognizing tumor endothelium and cancer cells through α4/VCAM-1 interaction. Once internalized by tumor cells, the CAI could be specifically released, which can not only inhibit CA IX to induce intracellular H+ accumulation for accelerating the Fenton reaction but also could prevent tumor metastasis because of the insufficient H+ formation outside cells for tumor extracellular matrix degradation. In addition, the HMFe can be employed to highly efficient magnetic resonance imaging to real-time monitor the agents’ bio-distribution and treatment progress. Both in vitro and in vivo results well demonstrated that the nanocatalysts could realize self-amplified CDT and breast cancer metastasis inhibition via tumor microenvironment remodeling, which also provides a promising paradigm for improving CDT and antimetastatic treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Enzyme function and inhibition

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, P.R. China

School of Medicine, Xiamen University, Xiamen 361102, P.R. China

Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, Shenzhen Zhongshan Institute for Reproduction and Genetics, Fertility Center, Shenzhen Zhongshan Urology Hospital, Shenzhen 518000, P.R. China

Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, P. R. China

Funding

National Natural Science Foundation of China · Youth Innovation Foundation of Xiamen City

References (40)

Show source-provided references
1. 10.1038/d41573-021-00018-610.1038/d41573-021-00018-6 ↗
2. 10.1016/j.msec.2021.11235110.1016/j.msec.2021.112351 ↗
3. 10.1016/j.jconrel.2021.05.01810.1016/j.jconrel.2021.05.018 ↗
4. 10.1016/j.actbio.2021.04.00610.1016/j.actbio.2021.04.006 ↗
5. 10.1016/j.jcis.2021.04.13110.1016/j.jcis.2021.04.131 ↗
6. 10.1016/j.jcis.2021.02.08510.1016/j.jcis.2021.02.085 ↗
7. 10.1002/adfm.20210464510.1002/adfm.202104645 ↗
8. 10.1016/j.jconrel.2020.03.00710.1016/j.jconrel.2020.03.007 ↗
9. 10.1038/nnano.2007.26010.1038/nnano.2007.260 ↗
10. 10.1002/anie.20200886810.1002/anie.202008868 ↗
11. 10.1002/anie.20180566410.1002/anie.201805664 ↗
12. 10.1016/j.apmt.2021.10118910.1016/j.apmt.2021.101189 ↗
13. 10.1021/acs.nanolett.6b0426910.1021/acs.nanolett.6b04269 ↗
14. 10.1021/ja809149g10.1021/ja809149g ↗
15. 10.1002/adfm.20190836510.1002/adfm.201908365 ↗
16. 10.3390/cancers1315384810.3390/cancers13153848 ↗
17. 10.3390/cancers1206161610.3390/cancers12061616 ↗
18. 10.1126/sciadv.abj036410.1126/sciadv.abj0364 ↗
19. 10.1517/13543776.2013.76952310.1517/13543776.2013.769523 ↗
20. 10.1158/0008-5472.CAN-10-426110.1158/0008-5472.CAN-10-4261 ↗
21. 10.1021/jacs.1c0387510.1021/jacs.1c03875 ↗
22. 10.1002/smll.20200586510.1002/smll.202005865 ↗
23. 10.1002/anie.20170857310.1002/anie.201708573 ↗
24. 10.1002/adhm.20210197110.1002/adhm.202101971 ↗
25. 10.1016/j.cej.2021.12890110.1016/j.cej.2021.128901 ↗
26. 10.1002/anie.20151003110.1002/anie.201510031 ↗
27. 10.1016/j.nantod.2021.10114610.1016/j.nantod.2021.101146 ↗
28. 10.1016/j.addr.2020.06.03010.1016/j.addr.2020.06.030 ↗
29. 10.1021/acsami.0c1687210.1021/acsami.0c16872 ↗
30. 10.1016/j.jconrel.2020.11.03910.1016/j.jconrel.2020.11.039 ↗
31. 10.1021/acsami.0c1723510.1021/acsami.0c17235 ↗
32. 10.1016/j.jconrel.2020.07.04510.1016/j.jconrel.2020.07.045 ↗
33. 10.1016/j.actbio.2020.04.05210.1016/j.actbio.2020.04.052 ↗
34. 10.1016/j.biomaterials.2020.11998610.1016/j.biomaterials.2020.119986 ↗
35. 10.1021/acsami.8b1164510.1021/acsami.8b11645 ↗
36. 10.1161/01.RES.77.6.119210.1161/01.RES.77.6.1192 ↗
37. 10.1111/j.1751-1097.2009.00555.x10.1111/j.1751-1097.2009.00555.x ↗
38. 10.1016/j.phrs.2019.02.00310.1016/j.phrs.2019.02.003 ↗
39. 10.1002/adfm.20200485110.1002/adfm.202004851 ↗
40. 10.1021/acsami.1c0331210.1021/acsami.1c03312 ↗